SCHEMBL2453066

SCHEMBL2453066

Oc1ccccc1/C(=N/N1CCCC1)n1ccnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
KMT2A Q03164 5/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
POLB P06746 3/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 2/20 0.38
GAA P10253 2/20 0.38
ADRB2 P07550 2/20 0.38
ADRB1 P08588 2/20 0.38
ADRB3 P13945 2/20 0.38
FAAH O00519 1/20 0.34
MGLL Q99685 1/20 0.34
NPC1 O15118 2/20 0.33
NR1I2 O75469 1/20 0.32
NR3C1 P04150 1/20 0.32
HTR1A P08908 1/20 0.32
ADORA3 P0DMS8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2453069 1.00 IDO1 (0.41) IDO1KMT2AALDH1A1MAPTMEN1
SCHEMBL2449583 0.99 MAPT (0.40) IDO1KMT2AALDH1A1MAPTMEN1
SCHEMBL2449581 0.99 MAPT (0.40) IDO1KMT2AALDH1A1MAPTMEN1
SCHEMBL2449411 0.99 MAPT (0.40) IDO1KMT2AALDH1A1MAPTMEN1
SCHEMBL2454553 0.85 MAPT (0.38) KMT2AALDH1A1MAPTMEN1GAA
SCHEMBL2454555 0.85 MAPT (0.38) KMT2AALDH1A1MAPTMEN1GAA
SCHEMBL2456250 0.84 MAPT (0.40) KMT2AALDH1A1MAPTMEN1POLB
SCHEMBL2456251 0.84 MAPT (0.40) KMT2AALDH1A1MAPTMEN1POLB
SCHEMBL2451785 0.84 MAPT (0.40) KMT2AALDH1A1MAPTMEN1POLB
SCHEMBL2451464 0.81 ADRB2 (0.43) KMT2AMAPTMEN1POLBADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 IDO1 10/4885KMT2A 1190/4885ALDH1A1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.